Trial Profile

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pralsetinib (Primary) ; Cabozantinib; Vandetanib
Indications Medullary thyroid cancer
Focus Therapeutic Use
Acronyms AcceleRET-MTC
Sponsors Roche

Most Recent Events

20 Mar 2024 This trial has been discontinued in Portugal (End Date: 30 Jun 2023), according to European Clinical Trials Database record.
08 Mar 2024 This trial has been discontinued in Italy(End Date: 30 Jun 2023), according to European Clinical Trials Database record.
04 Jan 2024 Planned initiation date changed from 30 Oct 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com